← 返回

采用基于平板的图像细胞术方法比较 CAR-T 细胞对悬浮肿瘤细胞的细胞毒性检测

英文原题:Comparison of chimeric antigen receptor-T cell-mediated cytotoxicity assays with suspension tumor cells using plate-based image cytometry method.

查看英文原题

Comparison of chimeric antigen receptor-T cell-mediated cytotoxicity assays with suspension tumor cells using plate-based image cytometry method.

PubMed 2022/08/03(内容时间) Cytometry A Q2 · IF 2.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

近十年来,嵌合抗原受体(CAR)T细胞疗法因治疗B细胞恶性肿瘤具有高效临床疗效和应答,改变了癌症治疗策略。其成功推动了针对不同肿瘤类型的多种CAR构建体研发,因此需要稳健高效的体外效力检测,快速从候选构建体库中筛选潜在CAR基因设计。图像细胞分析方法已用于多种CAR-T 细胞介导的细胞毒性检测,主要因操作简便、可捕获细胞图像用于验证且通量较高。本研究使用Celigo图像细胞分析仪,评估和比较两种CAR-T 细胞介导的细胞毒性检测法,靶细胞为表达GFP或荧光染料标记的骨髓瘤和浆细胞瘤细胞。与CMFDA/DAPI活性检测法相比,GFP方法检测CAR-T 细胞介导细胞毒性的敏感度更高。研究建立了选择适用目的细胞毒性检测方法的标准和注意事项,以确保结果适合特定测试条件并具有意义。

展开英文摘要原文

In the recent decade, chimeric antigen receptor (CAR)-T cell therapy has revolutionized strategies for cancer treatments due to its highly effective clinical efficacy and response for B cell malignancies. The success of CAR-T cell therapy has stimulated the increase in the research and development of various CAR constructs to target different tumor types.

Therefore, a robust and efficient in vitro potency assay is needed to quickly identify potential CAR gene design from a library of construct candidates. Image cytometry methodologies have been utilized for various CAR-T cell-mediated cytotoxicity assay using different fluorescent labeling methods, mainly due to their ease-of-use, ability to capture cell images for verification, and higher throughput performance.

In this work, we employed the Celigo Image Cytometer to evaluate and compare two CAR-T cell-mediated cytotoxicity assays using GFP-expressing or fluorescent dye-labeled myeloma and plasmacytoma cells. The GFP-based method demonstrated higher sensitivity in detecting CAR-T cell-mediated cytotoxicity when compared to the CMFDA/DAPI viability method.

We have established the criteria and considerations for the selection of cytotoxicity assays that are fit-for-purpose to ensure the results produced are meaningful for the specific testing conditions.

论文信息

作者
Sun YJ、Chen YC、Hua WK、Wu SC、Chan LL
第一作者单位
Department of Research and Development, GenomeFrontier Therapeutics, Taipei City, Taiwan.Taiwan
通讯作者单位
Department of Advanced Technology R&D, Nexcelom from PerkinElmer, Lawrence, Massachusetts, USA.United States
期刊
Cytometry. Part A : the journal of the International Society for Analytical Cytology2023 Jan
原文标识
PubMed 35869932 · DOI 10.1002/cyto.a.24673